- Home
- FICO vs TAK Comparison
FICO vs TAK Comparison
Compare FICO & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FICO
- TAK
- Stock Information
- Founded
- FICO 1956
- TAK 1781
- Country
- FICO United States
- TAK Japan
- Employees
- FICO N/A
- TAK N/A
- Industry
- FICO Business Services
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- FICO Consumer Discretionary
- TAK Health Care
- Exchange
- FICO Nasdaq
- TAK Nasdaq
- Market Cap
- FICO 48.4B
- TAK 47.0B
- IPO Year
- FICO 1987
- TAK N/A
- Fundamental
- Price
- FICO $2,089.48
- TAK $14.37
- Analyst Decision
- FICO Buy
- TAK
- Analyst Count
- FICO 12
- TAK 0
- Target Price
- FICO $2,236.75
- TAK N/A
- AVG Volume (30 Days)
- FICO 177.1K
- TAK 2.0M
- Earning Date
- FICO 04-29-2025
- TAK 05-08-2025
- Dividend Yield
- FICO N/A
- TAK 4.08%
- EPS Growth
- FICO 21.78
- TAK N/A
- EPS
- FICO 23.21
- TAK 0.45
- Revenue
- FICO $1,840,361,000.00
- TAK $30,595,075,281.00
- Revenue This Year
- FICO $17.79
- TAK $0.87
- Revenue Next Year
- FICO $15.57
- TAK $1.69
- P/E Ratio
- FICO $89.95
- TAK $63.69
- Revenue Growth
- FICO 14.71
- TAK 7.45
- 52 Week Low
- FICO $1,240.31
- TAK $12.58
- 52 Week High
- FICO $2,402.52
- TAK $15.37
- Technical
- Relative Strength Index (RSI)
- FICO 65.74
- TAK 40.48
- Support Level
- FICO $2,035.94
- TAK $14.22
- Resistance Level
- FICO $2,112.05
- TAK $15.43
- Average True Range (ATR)
- FICO 56.11
- TAK 0.20
- MACD
- FICO 14.31
- TAK -0.08
- Stochastic Oscillator
- FICO 85.76
- TAK 11.98
About FICO Fair Isaac Corproation
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's credit scores business accounts for most of the firm's profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.